Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer

Luigi Tarantini, Giovanni Cioffi, Stefania Gori, Fausto Tuccia, Lidia Boccardi, Daniella Bovelli, Chiara Lestuzzi, Nicola Maurea, Stefano Oliva, Giulia Russo, Pompilio Faggiano

Research output: Contribution to journalArticlepeer-review


Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalJournal of Cardiac Failure
Issue number2
Publication statusPublished - Feb 2012


  • adjuvant chemotherapy
  • Breast cancer
  • cardiotoxicity
  • heart failure
  • trastuzumab

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer'. Together they form a unique fingerprint.

Cite this